Shareholders in Shandong Weigao Group Medical Polymer (HKG:1066) Are in the Red If They Invested Three Years Ago
Shareholders in Shandong Weigao Group Medical Polymer (HKG:1066) Are in the Red If They Invested Three Years Ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term shareholders of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) have had an unfortunate run in the last three years. So they might be feeling emotional about the 62% share price collapse, in that time. The more recent news is of little comfort, with the share price down 61% in a year. The falls have accelerated recently, with the share price down 30% in the last three months.
事实是,如果你投资足够长的时间,你最终会有一些亏损的股票。但是,山东威高集团医用聚合物有限公司(HKG: 1066)的长期股东在过去三年中出现了不幸的挤兑情况。因此,他们可能会对那段时间内62%的股价暴跌感到激动。最近的消息并不令人欣慰,股价在一年内下跌了61%。最近跌势加速,股价在过去三个月中下跌了30%。
It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.
值得评估的是,该公司的经济状况是否与这些令人难以置信的股东回报步调一致,或者两者之间是否存在一些差距。所以我们就这么做吧。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。评估公司情绪变化的一种有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
Although the share price is down over three years, Shandong Weigao Group Medical Polymer actually managed to grow EPS by 7.2% per year in that time. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.
尽管股价在三年内下跌,但在此期间,山东威高集团医用聚合物实际上每年增长7.2%。这真是个难题,表明可能会有一些东西暂时提振股价。否则,该公司过去曾被过度炒作,因此其增长令人失望。
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
由于每股收益的变化似乎与股价的变化无关,因此值得一看其他指标。
We note that, in three years, revenue has actually grown at a 7.8% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Shandong Weigao Group Medical Polymer further; while we may be missing something on this analysis, there might also be an opportunity.
我们注意到,在三年内,收入实际上以7.8%的年增长率增长,因此这似乎不是出售股票的理由。可能值得进一步研究山东威高集团医用聚合物;虽然我们在分析中可能遗漏了一些东西,但也可能有机会。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下图显示了收入和收入随时间推移的跟踪情况(如果您点击图片,可以看到更多细节)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240302/0-f55bf68f8393af2b33709ed8fdbab97f-0-351ca18999cd0e0f3a5c71378d328549.png/big)
Take a more thorough look at Shandong Weigao Group Medical Polymer's financial health with this free report on its balance sheet.
通过这份免费的资产负债表报告,更全面地了解山东威高集团医用聚合物的财务状况。
A Different Perspective
不同的视角
We regret to report that Shandong Weigao Group Medical Polymer shareholders are down 60% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 11%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 4% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Shandong Weigao Group Medical Polymer better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Shandong Weigao Group Medical Polymer you should know about.
我们遗憾地报告,山东威高集团医用聚合物股东今年下跌了60%(甚至包括股息)。不幸的是,这比整个市场11%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中4%的年化亏损还要糟糕。我们意识到罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。长期跟踪股价表现总是很有意思的。但是,要更好地了解山东威高集团医用聚合物,我们需要考虑许多其他因素。例如,考虑风险。每家公司都有它们,我们发现了你应该知道的山东威高集团医用聚合物的一个警告信号。
Of course Shandong Weigao Group Medical Polymer may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然,山东威高集团医用聚合物可能不是最好的买入股票。因此,您可能希望看到这批免费的成长股。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。